Compare DexCom, Inc. (DXCM) vs Rivian Automotive, Inc. (RIVN) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Rivian stock trades at $16.91, down 3.37% on the day, as the EV maker continues its transition toward profitability. Recent earnings beats and the upcoming R2 vehicle launch provide optimism, though negative cash flow and substantial losses remain concerns. Technical indicators show a bullish trend with support at $16 and resistance at $18-19, while analyst consensus favors a buy rating with a $19.22 price target.

The investment case hinges on Rivian's ability to scale production and achieve profitability, with the R2 launch representing a potential inflection point. Key risks include ongoing cash burn, competitive pressures, and execution challenges in a capital-intensive industry. Upside potential exists if the company can demonstrate sustainable margin improvement and demand strength for new models.